Page 178 - பல்கலைக்கழகம் ஆஃப் நெப்ராஸ்கா மருத்துவ மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Dec 15, 2020 MONDAY, Dec. 14, 2020 (HealthDay News) For hospitalized adults with COVID-19, baricitinib plus remdesivir is better for reducing recovery time and improving clinical status than remdesivir alone, according to a study published online Dec. 11 in the New England Journal of Medicine. Andre C. Kalil, M.D., M.P.H., from the University of Nebraska Medical Center in Omaha, and colleagues conducted a randomized, placebo-controlled trial examining baricitinib plus remdesivir in hospitalized adults with COVID-19. A total of 1,033 patients were randomly assigned: 515 were assigned to receive baricitinib plus remdesivir (combination treatment) and 518 to placebo plus remdesivir (control). The researchers found that the median time to recovery was seven and eight days for combination treatment versus control (rate ratio for recovery, 1.16; 95 percent confidence interval [CI], 1.01 to 1.32; P = 0.03). Patients receiving baricitinib had higher odds of improvement in clinical sta

Andrec kalilEli lillyGilead sciencesUniversity of nebraska medical centerHealthday newsNew england journalNebraska medical centerஎலி லில்லிகிலியட் அறிவியல்பல்கலைக்கழகம் ஆஃப் நெப்ராஸ்கா மருத்துவ மையம்புதியது இங்கிலாந்து இதழ்நெப்ராஸ்கா மருத்துவ மையம்